Get the Stockscreener App
8.57
1.38%
-0.12
Iteos Therapeutics Inc stock is traded at $8.57, with a volume of 461.21K.
It is down -1.38% in the last 24 hours and up +19.86% over the past month.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.
See More
Previous Close:
$8.69
Open:
$8.57
24h Volume:
461.21K
Relative Volume:
0.56
Market Cap:
$327.97M
Revenue:
$127.70M
Net Income/Loss:
$-121.25M
P/E Ratio:
-2.7206
EPS:
-3.15
Net Cash Flow:
$-120.32M
1W Performance:
+9.73%
1M Performance:
+19.86%
6M Performance:
+3.00%
1Y Performance:
-51.14%
1-Day Range:
$8.45
$8.87
1-Week Range:
$8.055
$8.87
52-Week Range:
$4.80
$18.13
Iteos Therapeutics Inc Stock (ITOS) Company Profile
Name
Iteos Therapeutics Inc
Sector
Industry
Phone
857-204-4583
Address
321 ARSENAL STREET, WATERTOWN
Compare ITOS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ITOS
Iteos Therapeutics Inc
|
8.57 | 305.04M | 127.70M | -121.25M | -120.32M | -3.15 |
|
ONC
Beigene Ltd Adr
|
240.58 | 24.41B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
435.40 | 111.55B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.335 | 42.47M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
588.45 | 63.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
74.81 | 5.92B | 0 | -153.72M | -103.81M | -2.00 |
Iteos Therapeutics Inc Stock (ITOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-14-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-14-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| May-13-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-13-24 | Initiated | Wells Fargo | Overweight |
| May-05-21 | Initiated | H.C. Wainwright | Buy |
| Oct-08-20 | Initiated | Robert W. Baird | Outperform |
| Aug-18-20 | Initiated | JP Morgan | Overweight |
| Aug-18-20 | Initiated | Piper Sandler | Overweight |
| Aug-18-20 | Initiated | SVB Leerink | Outperform |
| Aug-18-20 | Initiated | Wedbush | Outperform |
View All
Iteos Therapeutics Inc Stock (ITOS) Latest News
(ITOS) Trading Advice - news.stocktradersdaily.com
Balyasny Asset Management L.P. Buys Shares of 28,350 iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
Q2 Earnings Forecast for ITOS Issued By Leerink Partnrs - Defense World
Q4 Earnings Forecast for ITOS Issued By Leerink Partnrs - Defense World
The week in pharma: action, reaction and insight – week to May 16 - The Pharma Letter
Wall Street Analysts Think iTeos Therapeutics (ITOS) Could Surge 212.5%: Read This Before Placing a Bet - MSN
Research Analysts Issue Forecasts for ITOS Q2 Earnings - Defense World
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Receives $18.83 Average Target Price from Analysts - Defense World
iTeos Therapeutics (NASDAQ:ITOS) Rating Lowered to “Hold” at Leerink Partnrs - Defense World
Leerink Partners Reiterates “Market Perform” Rating for iTeos Therapeutics (NASDAQ:ITOS) - Defense World
ITOS: ITeos Therapeutics Downgraded to Neutral by HC Wainwright & Co. | ITOS Stock News - GuruFocus
iTeos Therapeutics: End To Belrestotug Program Leads To A Hold Rating (NASDAQ:ITOS) - Seeking Alpha
Piper Sandler cuts iTeos stock price target to $12 from $16 - Investing.com Canada
ITeos Therapeutics (ITOS) Sees Price Target Adjustment by Piper Sandler | ITOS Stock News - GuruFocus
iTeos, GSK End Collaboration On Experimental Cancer Therapy Development: But Retail’s Extremely Bullish - NewsBreak: Local News & Alerts
ITeos Therapeutics (ITOS): Analyst Lowers Price Target, Rating R - GuruFocus
Strategic Shift and Strong Financials Position iTeos Therapeutics for Growth - TipRanks
ITeos Therapeutics (ITOS) Downgraded by Leerink Partners | ITOS Stock News - GuruFocus
This Wayfair Analyst Turns Bearish; Here Are Top 4 Downgrades For Wednesday - Benzinga
Leerink Downgrades iTeos Therapeutics to Market Perform From Outperform - marketscreener.com
HC Wainwright Downgrades iTeos Therapeutics to Neutral From Buy - marketscreener.com
iTeos Therapeutics (ITOS) Receives Adjusted Price Target from We - GuruFocus
iTeos Therapeutics (ITOS) Receives Adjusted Price Target from Wells Fargo | ITOS Stock News - GuruFocus
iTeos Therapeutics (ITOS) Faces Downgrade Following GSK's Decisi - GuruFocus
GSK (GSK) and iTeos Halt Belrestotug Development After Disappoin - GuruFocus
iTeos Therapeutics price target lowered to $12 from $16 at Piper Sandler - TipRanks
iTeos Therapeutics (ITOS) Faces Downgrade Following GSK's Decision | ITOS Stock News - GuruFocus
GSK (GSK) and iTeos Halt Belrestotug Development After Disappointing Trial Results | GSK Stock News - GuruFocus
iTeos Therapeutics (ITOS) Downgraded by Analyst with New Price T - GuruFocus
Leerink downgrades iTeos Therapeutics after termination of TIGIT program - TipRanks
iTeos and GSK halt lung cancer drug development By Investing.com - Investing.com India
GSK, partner iTeos end development programme for lung cancer drug belrestotug - Medical Dialogues
ITeos Therapeutics (ITOS) Downgraded by JP Morgan | ITOS Stock N - GuruFocus
As iTeos, GSK shelve belrestotug, prospects for TIGIT continue to dim - biocentury.com
iTeos Therapeutics: TIGIT Falls, And A Zombie Rises? (NASDAQ:ITOS) - Seeking Alpha
iTeos/GSK To Terminate Collaboration After TIGIT Trials Flop - insights.citeline.com
JPMorgan cuts iTeos Therapeutics stock rating to neutral, target to $8 - Investing.com Australia
GSK and iTeos end belrestotug antibody program By Investing.com - Investing.com Nigeria
JPMorgan cuts iTeos Therapeutics stock rating to neutral, target to $8 By Investing.com - Investing.com Nigeria
iTeos Therapeutics (ITOS) Downgraded by JPMorgan Analyst | ITOS Stock News - GuruFocus
GSK, partner iTeos scrap development of lung cancer therapy - NewsBreak: Local News & Alerts
iTeos Stock Soars Despite Trial Setback On Liquidation Buzz And Solid Cash PileITeos Therapeutics (NASDAQ:ITOS) - Benzinga
iTeos and GSK to drop belrestotug + dostarlimab collaboration - The Pharma Letter
iTeos Reports Topline Interim Results from GALAXIES Lung-201 Stu - GuruFocus
iTeos, GSK to shelve TIGIT drug after study setback - BioPharma Dive
ITeos Terminates TIGIT Program After Phase 2 Lung Study Misses PFS Endpoint, Explores Options - Nasdaq
ITeos, GSK discontinue lung cancer therapy development - KFGO
Wedbush Adjusts Price Target on iTeos Therapeutics to $10 From $25, Maintains Outperform Rating - marketscreener.com
GSK (GSK) and iTeos Halt Development of Lung Cancer Drug Combo - GuruFocus
GSK, iTeos Therapeutics End Belrestotug Development Program - marketscreener.com
iTeos stock rises despite clinical trial setback By Investing.com - Investing.com South Africa
Iteos Therapeutics Inc Stock (ITOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
17.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):